Research

Found 141,973 articles

• 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

  3/22/2023

  89bio, Inc. today announced positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

• A NEW STUDY SUGGESTS ENERGY4LIFE'S BIOENERGETIC WEARABLE DEVICE MAY HAVE POSITIVE EFFECTS ON CELLULAR MEMBRANE

  3/22/2023

  A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures.

• WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

  3/22/2023

  WILLOW BIOSCIENCES, (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG).

• Axon Therapies Cohort Study Extends Benefit to 6 months with Early Clinical Data from REBALANCE-HF Randomized Clinical Trial

  3/22/2023

  Axon Therapies today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF.

• Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

  3/22/2023

  Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology.

• PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate

  3/22/2023

  PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.

• Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with CancerVAX CEO Ryan Davies

  3/22/2023

  CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, announced that CEO Ryan Davies spoke with world-renown diabetes researcher Dr. Jonathan Lakey.

• 

  Mereo Forges Ahead with PRO Trial Design for Lung Disease Program

  3/21/2023

  Following recent meetings with the FDA and European Medicines Agency, Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.
• 

  With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS' Yervoy

  3/21/2023

  BioNTech inked an exclusive worldwide license and collaboration agreement with OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors.

• Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

  3/21/2023

  Halberd Corporation, leading up to the scheduled meeting with the Centers for Disease Control on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E.

• Alveo Technologies Announces ISO 13485:2016 Certification

  3/21/2023

  Alveo Technologies, Inc. today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease.

• Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal

  3/21/2023

  Lumicell, Inc. today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been submitted to the U.S. Food and Drug Administration (FDA).

• Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

  3/21/2023

  Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal.

• Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

  3/21/2023

  Scilex Holding Company announced that it has entered into a securities purchase agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP (”Yorkville”), for the issuance and sale of unsecured convertible debentures in the principal amount of up to $25 million.

• Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

  3/21/2023

  Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia.

• Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

  3/21/2023

  Adial Pharmaceuticals, Inc. today announced it has engaged The Keswick Group, LLC, a biotech strategic commercial and business development advisory firm, to advance the Company’s partnering activities.

• PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY'S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST

  3/21/2023

  Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™. 

• Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

  3/21/2023

  Protalix BioTherapeutics, Inc. today announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treatment of severe gout.

• Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

  3/21/2023

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes.

• Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

  3/21/2023

  Numinus Wellness Inc. today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.